# Intractable Pediatric Epilepsy & Seizure Disorders: Clinical Cannabinoid Guide | CĒD Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pediatrics/epilepsy/ > **Published:** 2026-09-27T18:12:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T18:12:32-04:00 > **Clinical Summary:** Home › Pediatric Cannabinoid Medicine › Medical Cannabis for Intractable Pediatric Epilepsy & Seizure Disorders Refractory Seizure Disorders PEDIATRIC NEUROLOGY & SEIZURE DISORDERS Medical Cannabis for Intractable Pediatric Epilepsy & Seizure Disorders Intractable pediatric epilepsy—including Dravet syndrome, Lennox-Gastaut syndrome, and refractory focal seizures—poses severe developmental and safety risks. When multiple anti-seizure medications fail to control […] --- [Home](https://cedclinic.com/) › [Pediatric Cannabinoid Medicine](https://cedclinic.com/pediatrics/) › [Medical Cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) for Intractable Pediatric Epilepsy & Seizure Disorders Refractory Seizure Disorders PEDIATRIC NEUROLOGY & SEIZURE DISORDERS Table of Contents - [Medical Cannabis for Intractable Pediatric Epilepsy & Seizure Disorders](#Medical_Cannabis_for_Intractable_Pediatric_Epilepsy_038_Seizure_Disorders)[When Is Cannabinoid Therapy Appropriate for Pediatric Epilepsy?](#When_Is_Cannabinoid_Therapy_Appropriate_for_Pediatric_Epilepsy) - [The Challenge of Drug-Resistant Pediatric Seizures](#The_Challenge_of_Drug-Resistant_Pediatric_Seizures) - [How Cannabinoids Modulate Neural Excitability](#How_Cannabinoids_Modulate_Neural_Excitability) - [Crucial Therapeutic Drug Monitoring & Pediatrician Collaboration](#Crucial_Therapeutic_Drug_Monitoring_038_Pediatrician_Collaboration)[Need Expert Clinical Guidance for Your Child?](#Need_Expert_Clinical_Guidance_for_Your_Child) # Medical Cannabis for Intractable Pediatric Epilepsy & Seizure Disorders Intractable pediatric epilepsy—including Dravet syndrome, Lennox-Gastaut syndrome, and refractory focal seizures—poses severe developmental and safety risks. When multiple anti-seizure medications fail to control electrical storm activity, clinical [cannabinoid therapy](https://cedclinic.com/cbd-gummies-libido-enhancement/) offers a proven neurological mechanism to reduce seizure frequency and severity. Clinical Director: **Benjamin Caplan, MD** Clinical Standard: **Refractory / Treatment-Resistant Cases Only** Oversight: **Frequent Physician Monitoring** ### When Is Cannabinoid Therapy Appropriate for Pediatric Epilepsy? **Clinical Appropriateness Standard:** Cannabinoid therapy is strictly indicated for pediatric patients with drug-resistant epilepsy (failing two or more appropriately chosen and tolerated antiepileptic drug regimens). It is utilized under the co-management of the child’s pediatric epileptologist to target refractory drop attacks, tonic-clonic convulsions, or daily clustering that threatens cognitive development and physical safety. ## The Challenge of Drug-Resistant Pediatric Seizures Approximately one-third of pediatric epilepsy patients remain refractory to conventional pharmaceutical medications. Living with intractable seizures involves: - Cumulative risk of status epilepticus, sudden unexpected death in epilepsy (SUDEP), and catastrophic physical injuries from drop attacks. - Severe polypharmacy side effects: cognitive blunting, behavioral regression, ataxia, and hepatic stress from high-dose antiepileptic combinations. - Profound sleep fragmentation and autonomic exhaustion following prolonged nocturnal seizure clusters. ## How Cannabinoids Modulate Neural Excitability The anti-seizure efficacy of Cannabidiol (CBD) has been established in landmark randomized, double-blind, placebo-controlled clinical trials (published in the *New England Journal of Medicine* and *The Lancet*): - **GPR55 Receptor Antagonism:** CBD blocks GPR55 G-protein-coupled receptors, attenuating intracellular calcium release and reducing excessive presynaptic excitatory glutamate transmission. - **TRPV1 Desensitization:** Cannabinoids rapidly desensitize transient receptor potential vanilloid 1 (TRPV1) channels, preventing sustained hyperexcitability and neuronal bursting. - **Adenosine Reuptake Inhibition:** CBD enhances extracellular adenosine levels, activating inhibitory A1 receptors to suppress cortical seizure generation. ## Crucial Therapeutic Drug Monitoring & Pediatrician Collaboration Cannabinoid care in epilepsy requires meticulous pharmacokinetic oversight. Cannabidiol inhibits CYP2C19, which can significantly elevate active N-desmethylclobazam levels in patients taking Clobazam (Onfi), potentially causing sedation unless monitored. At CĒD Clinic, we mandate baseline and periodic serum antiepileptic level testing, liver function panels, and direct collaboration with your pediatric neurology team. The CĒD Clinic Clinical Process for Pediatric Patients Cannabinoid medicine is never casual or one-size-fits-all. Every pediatric patient undergoes structured, conservative physician oversight to ensure maximum safety, legal protection, and clinical efficacy. 1 Comprehensive Intake & Records Review We conduct a meticulous review of prior diagnostic evaluations, failed medications, laboratory work, and specialist records. We verify refractory criteria and screen for CYP450 drug-drug interactions. 2 Customized Care Plan & Product Guidance Dr. Caplan formulates an individualized botanical care plan specifying exact cannabinoid ratios (CBD, CBDA, CBG, CBC), administration routes, and verified, third-party lab-tested (COA) products. 3 Conservative Micro-Titration Protocol Therapy begins at low, sub-therapeutic micro-doses. Families log daily symptom metrics using our clinic tracking journals, adjusting dosages gradually every 7 to 14 days under physician supervision. 4 Frequent Oversight & Team Coordination We provide frequent follow-ups, adjust formulations as the child grows, and communicate directly with your child’s primary care pediatrician, neurologist, or psychiatrist to ensure coordinated care. #### Need Expert Clinical Guidance for Your Child? Schedule a confidential consultation to explore whether cannabinoid therapy is appropriate for your family. [Schedule Consultation](https://cedclinic.com/contact/) [← Return to Pediatrics Overview](https://cedclinic.com/pediatrics/) --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).